Charles River Laboratories International, Inc. (NYSE:CRL) Shares Purchased by Sumitomo Mitsui Trust Group Inc.

Sumitomo Mitsui Trust Group Inc. lifted its position in Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) by 11.7% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 125,097 shares of the medical research company's stock after buying an additional 13,102 shares during the period. Sumitomo Mitsui Trust Group Inc. owned about 0.24% of Charles River Laboratories International worth $23,093,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently made changes to their positions in the company. Wellington Management Group LLP lifted its stake in shares of Charles River Laboratories International by 135,927.9% in the third quarter. Wellington Management Group LLP now owns 3,740,768 shares of the medical research company's stock worth $736,819,000 after buying an additional 3,738,018 shares in the last quarter. State Street Corp lifted its stake in shares of Charles River Laboratories International by 2.0% in the third quarter. State Street Corp now owns 2,130,279 shares of the medical research company's stock worth $419,601,000 after buying an additional 41,421 shares in the last quarter. Allspring Global Investments Holdings LLC lifted its stake in shares of Charles River Laboratories International by 40.7% in the third quarter. Allspring Global Investments Holdings LLC now owns 1,760,781 shares of the medical research company's stock worth $346,821,000 after buying an additional 509,163 shares in the last quarter. Charles Schwab Investment Management Inc. lifted its stake in shares of Charles River Laboratories International by 6.7% in the third quarter. Charles Schwab Investment Management Inc. now owns 515,222 shares of the medical research company's stock worth $101,483,000 after buying an additional 32,311 shares in the last quarter. Finally, JPMorgan Chase & Co. lifted its stake in shares of Charles River Laboratories International by 21.6% in the third quarter. JPMorgan Chase & Co. now owns 482,745 shares of the medical research company's stock worth $95,086,000 after buying an additional 85,759 shares in the last quarter. Institutional investors own 98.91% of the company's stock.

Charles River Laboratories International Stock Performance

CRL traded down $1.10 during trading on Friday, reaching $152.07. 841,129 shares of the company's stock were exchanged, compared to its average volume of 1,002,698. Charles River Laboratories International, Inc. has a 1 year low of $150.79 and a 1 year high of $275.00. The company has a debt-to-equity ratio of 0.61, a current ratio of 1.48 and a quick ratio of 1.14. The stock has a market capitalization of $7.78 billion, a P/E ratio of 19.03, a price-to-earnings-growth ratio of 6.47 and a beta of 1.37. The company's fifty day simple moving average is $176.43 and its 200-day simple moving average is $190.73.

Analysts Set New Price Targets

Several brokerages have recently issued reports on CRL. Evercore ISI upped their target price on shares of Charles River Laboratories International from $190.00 to $225.00 and gave the stock an "in-line" rating in a research note on Thursday, November 7th. Morgan Stanley decreased their price objective on shares of Charles River Laboratories International from $220.00 to $184.00 and set an "equal weight" rating for the company in a report on Wednesday, February 5th. William Blair cut shares of Charles River Laboratories International from an "outperform" rating to a "market perform" rating in a report on Wednesday, January 22nd. Bank of America decreased their price objective on shares of Charles River Laboratories International from $220.00 to $210.00 and set a "neutral" rating for the company in a report on Friday, December 13th. Finally, JPMorgan Chase & Co. decreased their price objective on shares of Charles River Laboratories International from $215.00 to $175.00 and set a "neutral" rating for the company in a report on Monday, February 3rd. Three equities research analysts have rated the stock with a sell rating, fourteen have assigned a hold rating and one has issued a buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of "Hold" and a consensus target price of $200.79.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).